EYPT

Research · Sep 29, 2026

Kodiak (KOD) Six-Month Wet AMD Data Raises the Bar for REGENXBIO (RGNX)

Kodiak's Zenkuda matched aflibercept in Phase 3 with 54% of patients on six-month dosing, resetting the bar that REGENXBIO's sura-vec gene therapy must clear in Q4 2026.